An impurity in the bulk drug lisinopril was detected by simple reversed-phase high-performance liquid chromatography (HPLC). This trace-level impurity was rapidly identified as 2-(2-oxo-azocan-3-ylamino)-4-phenyl-butyric acid on the basis of the on-line multi-stage mass spectrometric evidence and the proposed structure was further confirmed by multi-stage mass spectrometry of lisinopril and three related compounds.
LancasterS.G.ToddP.A., “Drugs Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure”, Drugs35, 646 (1988).
2.
GoaK.L.BalfourJ.A.ZuanettiG., “Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction”, Drugs52, 564 (1996).
3.
SimpsonK.JarvisB., “Lisinopril. A review of its use in congestive heart failure. Drugs59, 1149 (2000).
4.
ErmerJ.VogelM., “Applications of hyphenated LC-MS techniques in pharmaceutical analysis”, Biomed. Chromatogr.14, 373 (2000). doi: 10.1002/1099-0801(200010)14:6<373::AID-BMC29>3.0.CO;2-S
5.
TevellA.BonessonU.TörnekeK.HedelandM., “Identification of some new clemastine metabolites in dog, horse, and human urine with liquid chromatography/tandem mass spectrometry”, Rapid Commun. Mass Spectrom.18(19), 2267 (2004). doi: 10.1002/rcm.1622
6.
KumarY.R.BabuJ.M.SarmaM.S.P.SeshidharB.ReddyS.S.ReddyG.S.YasK., “Application of LC-MS/MS for the identification of a polar impurity in mosapride, a gas-troprokinetic drug”J. Phamaceut. Biomed. Anal.32(2), 361 (2003). doi: 10.1016/S0731-7085(03)00076-1
7.
VähätaloJ.TuominenJ.KokkonenJ.KřížO.KaronenS.KallioM., “Trace impurities identified by high performance liquid chromatography/electrospray mass spectrometry in two different synthetic batches of 4-boronophenylalanine”, Rapid Commun. Mass Spectrom.12(16), 1118 (1998). doi: 10.1002/(SICI)1097-0231(19980831)12:16<1118::AID-RCM289>3.0.CO;2-1
8.
BurinskyD.J.SidesS.L., “Mass Spectral Fragmentation Reactions of Angiotensin- Converting Enzyme (ACE) Inhibitors”, Journal of the American Society for Mass Spectrometry15(9), 1300 (2004). doi: 10.1016/j.jasms.2004.05.010
9.
FlorêncioM.H.FernandezM.T.MiraM.L.MillarA.JenningsK.R., “Electrospray Mass Spectrometry of Angiotensin-converting Enzyme Inhibitors”, Rapid Commun. Mass Spectrom.12(23), 1928 (1998). doi: 10.1002/(SICI)1097-0231(19981215)12:23<1928::AID-RCM405>3.0.CO;2-W
10.
MilneG.W.A.AxenrodT.FalesH.M., “Chemical ionization mass spectrometry of complex molecules. VI. Amino acids”, J. Am. Chem. Soc.92(17), 5170 (1970). doi: 10.1021/ja00720a029
11.
BuchonnetS.DenhezJ.P.HoppilliardY.MauriacC., “Is plasma desorption mass spectrometry useful for small molecule analysis? Fragmentations of the natural alpha-amino acids”, Anal. Chem.64(7), 743 (1992). doi: 10.1021/ac00031a009
12.
YalcinT.KhouwC.CsizmadiaI.G.PetersonM.R.HarrisonA.G., “Why are B ions stable species in peptide spectra?”, J. Am. Soc. Mass Spectrom.6(12), 1165 (1995).
13.
TsangC.W.HarrisonA.G., “Chemical ionization of amino acids”, J. Am. Chem. Soc.98(6), 1301 (1976). doi: 10.1021/ja00422a001
14.
CorderoM.M.HouserJ.J.WesdemiotisC., “The neutral products formed during backbone fragmentations of protonated peptides in tandem mass spectrometry”, Anal. Chem.65(11), 1594 (1993). doi: 10.1021/ac00059a019
15.
BeranováS.CaiJ.WesdemiotisC., “Unimolecular chemistry of protonated glycine and its neutralized form in the gas phase”, J. Am. Chem. Soc.117(37), 9492 (1995). doi: 10.1021/ja00142a016
16.
YalcinT.HarrisonA.G., “Ion Chemistry of protonated Lysine Derivatives”, J. Mass Spectrom.31, 1237 (1996). doi: 10.1002/(SICI)1096-9888(199611)31:11<1237::AID-JMS416>3.0.CO;2-P
17.
KishM.M.WesdemiotisC., “Selective cleavage at internal lysine residues in protonated vs. metalated peptides”, Int. J. Mass Spectrom.227, 191 (2003). doi: 10.1016/S1387-3806(03)00069-1
18.
SunA.M.ZhiY.H., “Synthetic method for lisinopril”, CN patent 1140708 (1997).
